Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2018

Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2018

Summary

clinical trial report, Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2018" provides an overview of Benign Prostatic Hyperplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Benign Prostatic Hyperplasia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).The Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Benign Prostatic Hyperplasia to Male Health Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Benign Prostatic Hyperplasia to Male Health Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Benign Prostatic Hyperplasia Therapeutics Clinical Trials 35
Prominent Drugs 37
Clinical Trial Profile Snapshots 38
Appendix 440
Abbreviations 440
Definitions 440
Research Methodology 441
Secondary Research 441
About GlobalData 441
Contact Us 442
Source 442

List Of Tables


Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials by Region, 2018* 7
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Benign Prostatic Hyperplasia to Male Health Clinical Trials, G7 Countries (%), 2018* 17
Benign Prostatic Hyperplasia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Benign Prostatic Hyperplasia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Benign Prostatic Hyperplasia to Male Health Clinical Trials, E7 Countries (%), 2018* 22
Benign Prostatic Hyperplasia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Benign Prostatic Hyperplasia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials by Phase, 2018* 26
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Benign Prostatic Hyperplasia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37

List Of Figures


Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Benign Prostatic Hyperplasia to Male Health Clinical Trials, G7 Countries (%), 2018* 16
Benign Prostatic Hyperplasia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Benign Prostatic Hyperplasia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Benign Prostatic Hyperplasia to Male Health Clinical Trials, E7 Countries (%), 2018* 21
Benign Prostatic Hyperplasia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Benign Prostatic Hyperplasia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27
Benign Prostatic Hyperplasia Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Benign Prostatic Hyperplasia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Benign Prostatic Hyperplasia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37
GlobalData Methodology 441

Europe Benign Prostatic Hyperplasia Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe Benign Prostatic Hyperplasia market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by

USD 3000 View Report

Asia Pacific Benign Prostatic Hyperplasia Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Asia Pacific Benign Prostatic Hyperplasia market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD

USD 3000 View Report

Europe Benign Prostatic Hyperplasia Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe Benign Prostatic Hyperplasia market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by

USD 3000 View Report

Asia Pacific Benign Prostatic Hyperplasia Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Asia Pacific Benign Prostatic Hyperplasia market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available